Loading
Paper cited by one term page, one bottleneck page and eleven idea pages, indexed on Europe PMC as PubMed record 21296615 and published in The Lancet Oncology; the citing pages link this DOI, which is how the record was matched.
To develop a framework for the definition and classification of cancer cachexia a panel of experts participated in a formal consensus process, including focus groups and two Delphi rounds. Cancer cachexia was defined as a multifactorial syndrome defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. Its pathophysiology is characterised by a negative protein and energy balance driven by a variable combination of reduced food intake and abnormal metabolism. The agreed diagnostic criterion for cachexia was weight loss greater than 5%, or weight loss greater than 2% in individuals already showing depletion according to current bodyweight and height (body-mass index [BMI] <20 kg/m(2)) or skeletal muscle mass (sarcopenia). An agreement was made that the cachexia syndrome can develop progressively through various stages--precachexia to cachexia to refractory cachexia. Severity can be classified according to degree of depletion of energy stores and body protein (BMI) in combination with degree of ongoing weight loss. Assessment for classification and clinical management should include the following domains: anorexia or reduced food intake, catabolic drive, muscle mass and strength, functional and psychosocial impairment. Consensus exists on a framework for the definition and classification of cancer cachexia. After validation, this should aid clinical trial design, development of practice guidelines, and, eventually, routine clinical management.
Indexed on Europe PMC as PubMed record 21296615 (DOI 10.1016/s1470-2045(10)70218-7). Matched by DOI alone: one term page, one bottleneck page and eleven idea pages cite this DOI among their external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.
One term page, one bottleneck page and eleven idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
The first drug to reverse cancer cachexia mechanistically rather than by appetite stimulation, in a disease where weight loss stops chemotherapy being delivered; the phase 3 programme and the question of survival remain.
Enzyme replacement is cheap, guideline-recommended (NICE NG85) and under-prescribed; the National Pancreatic Cancer Audit now reports the prescribing rate as a performance indicator, which the UK and NHS page tracks.
Shares Enzyme replacement improves survival among patients with pancreatic cancer: Results of a population based study, Embed cachexia treatment in chemotherapy trials: weight, muscle and treatment delivery as co-primary endpoints, Cachexia, toxicity and the limits of the patient, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question.
Shares Ponsegromab for the Treatment of Cancer Cachexia, Embed cachexia treatment in chemotherapy trials: weight, muscle and treatment delivery as co-primary endpoints, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question.
Shares Test protein and resistance training during immunotherapy, Four weeks of training and nutrition before major cancer surgery, as standard, Pay for supervised exercise the way we pay for drugs, Cachexia, toxicity and the limits of the patient.
Shares Get the one approved appetite drug licensed beyond a single country, Treat cachexia as a disease: GDF-15 blockade plus anabolic and nutrition bundles, A cheap old tablet to restore appetite, Cancer cachexia.
Shares Catch wasting early with a smart scale and a step counter, Treat wasting like sepsis: a trigger, a bundle, an audit, Test protein and resistance training during immunotherapy, Get the one approved appetite drug licensed beyond a single country.
Shares Read muscle loss automatically from scans patients already have, Dose chemotherapy by muscle mass, not body surface area, Cancer cachexia, Cachexia, toxicity and the limits of the patient.
Shares Get the one approved appetite drug licensed beyond a single country, Cancer cachexia, Cachexia, toxicity and the limits of the patient.
Shares Ponsegromab for the Treatment of Cancer Cachexia, Cancer cachexia, Cachexia, toxicity and the limits of the patient.